Sunpure receives patent for Curcuminoids Complex AKTIV C5 (CURCUBOOST®)

New Delhi (India), August 22: Sunpure announced a milestone in its ongoing intellectual property mission. Sunpure has received a patent grant for Curcuminoids Complex AKTIV C5 (CURCUBOOST®) with enhanced bioavailable penta active components of Turmeric.

“We are thrilled to receive this patent, highlighting our commitment to innovation.  This patent (CURCUBOOST®) grant is a significant milestone for Sunpure Research Incubation Centre (SRIC), Sunpure Extracts Private Limited, and we look forward to bringing more such innovative health solutions and ingredients to our customers”, says Mr. Amit Srivastava (GM), Sunpure.

The application for the Invention of the Curcumin C5 AKTIV complex—CURCUBOOST® —was accepted in 2019, and after addressing various queries, it was granted in 2024. This patent will be in force until 2039.

The present invention envisioned chemical composition modification of the active molecules of Turmeric to use Curcuminoids with better Bioavailability and increased efficacy by using two additional ingredients: Turmeric Merone and Polysaccharides along with Curcuminoids, says Mr. Singh, Principal Scientist, SRIC (Sunpure Research Incubation Centre).

SRIC scientists work tirelessly to discover and develop standardised natural extracts that provide an alternative therapy for emerging nutritional and health requirements worldwide. This patent grant recognises the pioneering work accomplished in the IP domain by the SEPL Team.

This will benefit formulators economically, as using less CURCUBOOST will increase bioavailability, and enhanced absorption will lead to better efficacy.

“With its seamless application across various delivery mechanisms, this achievement reaffirms our dedication to pioneering technological integration of Ayurveda and modern science that redefine novel solutions. Our initiatives showcase our proactive commitment to environmental sustainability using whole biomass”, says Mr Saurabh Sharma (VP) of Sunpure.

The award recognises and celebrates Sunpure’s IP portfolio, which has embraced IP generation and protection to fuel economic growth and contribute to the country’s economic progress.

Sunpure has GMP certification and an Ayurvedic license from AYUSH.

About Sunpure Extracts Private Limited (SEPL)

Sunpure Extracts Private Limited (SEPL) has natural extract production facilities in UP and Uttarakhand and exports natural ingredients to over 32 countries. SEPL is globally known for B2B brands like AshwaBoost®, CurcuBoost®, SPIRUproteen®, MORIMAXproteen®, ZingiNatPure®, BOSWpure®, WKB20K®, TetraBeauty® FENUTEIN®, and CENTpure®. The company has successfully filed 14 US DMFs with the US FDA for a range of natural extracts and Botanicals and has applied for 4 patents. SEPL serves companies in the nutraceuticals, food supplements, pharma, personal care, flavour, and fragrance segments.

Media Contact:

Arun

If you object to the content of this press release, please notify pr.error.rectification@gmail.com. We will get back to you and fix the situation within 24 hours.

Health

Dr. Arpit Chopra Jain Honored at United Nations Headquarters in New York

New Delhi [India], June 17: Dr. Arpit Chopra Jain, a distinguished figure in the field of alternative medicine, was invited as the Guest of Honour at the prestigious United Nations Global Excellence Awards held at the United Nations Headquarters in New York, USA. The grand event, organized by the United Nations Global Peace Council, took […]

Read More
Health

TrueFits App: India’s Fitness Game-Changer with AI Power

Bengaluru (Karnataka) [India], June 16: In the past, people used to join gyms but often didn’t go regularly. The money was gone, but the health stayed the same. TrueFits changed this. It lets users pay only when they actually use a gym. This idea came from watching how people wasted money on unused gym plans. […]

Read More
Health

TRANSFORM II Trial Hits Enrollment Milestone: Redefining Coronary Care with Sirolimus-Coated Balloons

New Delhi [India], June 14: The Fondazione Ricerca e Innovazione Cardiovascolare (RIC) has successfully finished patient enrolment for TRANSFORM II, one of the most ambitious and extensive randomised controlled trials (RCTs) ever carried out in the field of cardiovascular care, at a pivotal point for the future of interventional cardiology.  In order to treat de-novo […]

Read More